Optimization of the cut-offs in acetylcholine receptor antibodies and diagnostic performance in myasthenia gravis patients

被引:6
|
作者
Shao, Kai [1 ]
Yue, Yao-Xian [2 ]
Zhao, Li-Ming [3 ]
Hao, Hong-Jun [4 ]
Ding, Xiao-Jun [5 ]
Jiang, Ping [6 ]
Yan, Chuan-Zhu [1 ,2 ]
Li, Hai-Feng [2 ,6 ]
机构
[1] Shandong Univ, Qilu Hosp Qingdao, Cheeloo Coll Med, Dept Cent Lab, Qingdao, Peoples R China
[2] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Neurol, Jinan, Peoples R China
[3] Linyi Peoples Hosp, Dept Nucl Med, Linyi, Peoples R China
[4] Peking Univ First Hosp, Lab Neuroimmunol, Beijing, Peoples R China
[5] Shandong Univ, Qilu Hosp Qingdao, Cheeloo Coll Med, Dept Neurol, Qingdao, Peoples R China
[6] Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
Acetylcholine receptor antibody; Cut; -off; Myasthenia gravis; Diagnostic performance; Agreement; OPTICA SPECTRUM DISORDER; ASSAY; AUTOANTIBODIES; TITERS;
D O I
10.1016/j.cca.2022.06.017
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objective: This study aims to establish an optimization procedure to define the cut-offs of quantitative assays for acetylcholine receptor antibody (AChRAb), evaluate their diagnostic performance in myasthenia gravis (MG), and explore the association with clinical features. Methods: Samples from a representative cohort of 77 MG patients, 80 healthy controls (HC) and 80 other autoimmune diseases (OAD) patients were tested using competitive inhibition ELISA and RIA. Raw values (OD and cpm) and processed values (inhibition rate, binding rate and concentration) were used to define the cut-offs with statistical methods, a rough method, and receiver operating characteristic (ROC) curve. Optimal cut-offs were selected by comparing false positive rates in HC and OAD individuals. The diagnostic performance was evaluated in whole MG cohort and subgroups. Agreement between ELISA and RIA for AChRAb positivity were examined with Kappa test and McNemar test. Clinical association with AChRAb was explored by comparison among subgroups and with Spearman rank correlation. Results: The optimal cut-offs for AChRAb positivity were determined as OD <= 1.79 for ELISA and cpm > 1234.12 for RIA, which derived from statistical method and performed better than those derived from ROC curves. The sensitivity and specificity were 74.03%, 100% for ELISA, and 74.03%, 99.37% for RIA. There was good agreement between ELISA and RIA for AChRAb positivity in whole cohort and subgroups (weighted k > 0.71, p < 0.01; McNemar test, p > 0.05). Levels of AChRAb were different in MG subgroups (p < 0.01). Correlation between Quantitative Myasthenia Gravis scores and AChRAb levels was moderate for ELISA and RIA (rs = -0.60 and 0.57, p < 0.01). Conclusion: The raw testing values of ELISA and RIA were found as optimal quantitative measures of AChRAb levels. There are good agreements on diagnostic performance between two assays. Quantitative values are more informative than positivity in association with clinical features.
引用
收藏
页码:122 / 130
页数:9
相关论文
共 50 条
  • [31] Clinical significance of detection of antibodies to fetal and adult acetylcholine receptors in myasthenia gravis
    Shi, Qi-Guang
    Wang, Zhi-Hong
    Ma, Xiao-Wei
    Zhang, Da-Qi
    Yang, Chun-Sheng
    Shi, Fu-Dong
    Yang, Li
    NEUROSCIENCE BULLETIN, 2012, 28 (05) : 469 - 474
  • [32] Development of a refined experimental mouse model of myasthenia gravis with anti-acetylcholine receptor antibodies
    You, Axel
    Lippens, Lea S.
    Fayet, Odessa-Maud
    Maillard, Solene
    Betemps, Laureline
    Grondin, Antony
    Vilquin, Jean-Thomas
    Dragin, Nadine
    Le Panse, Rozen
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [33] Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis
    Masuda, Tomoko
    Motomura, Masakatsu
    Utsugisawa, Kimiaki
    Nagane, Yuriko
    Nakata, Ruka
    Tokuda, Masahiro
    Fukuda, Taku
    Yoshimura, Toshiro
    Tsujihata, Mitsuhiro
    Kawakami, Atsushi
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2012, 83 (09) : 935 - 940
  • [34] Titin and ryanodine receptor antibodies in myasthenia gravis
    Skeie, GO
    Aarli, JA
    Gilhus, NE
    ACTA NEUROLOGICA SCANDINAVICA, 2006, 113 : 19 - 23
  • [35] Characterization of the nicotinic acetylcholine receptor antibodies after an unexpected increase of antibody titer in thymoma associated myasthenia gravis patients
    Zouvelou, Vasiliki
    Michail, Maria
    Belimezi, Maria
    Haroniti, Anna
    Zisimopoulou, Paraskevi
    NEUROMUSCULAR DISORDERS, 2022, 32 (10) : 847 - 850
  • [36] Autoimmune antibodies to collagen XIII in myasthenia gravis patients
    Tu, Hongmin
    Pirskanen-Matell, Ritva
    Heikkinen, Anne
    Oikarainen, Tuomo
    Risteli, Juha
    Pihlajaniemi, Taina
    MUSCLE & NERVE, 2018, 57 (03) : 506 - 510
  • [37] Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays
    Vincent, Angela
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2012, 83 (03) : 237 - 238
  • [38] Myasthenia Gravis Patients with Anti-MuSK Antibodies
    Zagar, Marija
    Vranjes, Davorka
    Sostarko, Marija
    Vogrinc, Zeljka
    Bilic, Ervina
    Cepe, Milica Trbojevic
    COLLEGIUM ANTROPOLOGICUM, 2009, 33 (04) : 1151 - 1154
  • [39] CLINICAL PERFORMANCE OF DIFFERENT TESTING PLATFORMS FOR DETECTION OF ACETYLCHOLINE-RECEPTOR AND MUSCLE-SPECIFIC KINASE ANTIBODIES IN MYASTHENIA GRAVIS
    Kumar, Pankaj
    Sodhi, Harvir
    Kihara, Eve
    Kaur, Navpreet
    Mousavi, Ali
    Aziz, Tariq
    Shyu, Clay
    Frykman, Hans
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2022, 27 : S153 - S153
  • [40] Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series
    Datta, Sorabh
    Singh, Shivangi
    Govindarajan, Raghav
    JOURNAL OF NEUROMUSCULAR DISEASES, 2020, 7 (03) : 269 - 277